Peking University Pharmaceuticals joint venture set up a cancer health management company.

On May 25, Peking University Pharmaceuticals announced that its subsidiary Beijing Beida Medical Oncology Hospital Management Co., Ltd. and Beijing Zhonglian New Investment Fund Management Co., Ltd. and Xin'an (Beijing) Medical Investment Consulting Co., Ltd. intend to sign the Investment Cooperation Framework Agreement on "North Swollen (Beijing) Health Management Co., Ltd." in the near future, with a three-way joint contribution of 50 million yuan to establish Beida (Beijing) Health Management Co., Ltd. Among them, the cancer management company contributed 30 million yuan, accounting for 60%.according to
data, Oncology Management Company is a joint venture between Peking University Pharmaceuticals and Beijing Peking University Medical Industry Management Co., Ltd., Peking University Cancer Hospital and Xin'an Medical Co., Ltd. in 2014. Among them, the company holds 41%, Peking University Cancer Hospital holds 34%, Xin'an Medical holds 15%, and industrial funds hold 10%. China Union Fund is a private equity, real estate, medical, pension investment and financing and real estate securitization business integrated investment fund management company, was established in 2013, registered capital of 30 million yuan. Cardio-SanMedical is a large-scale medical investment and financial services company based on medical investment, consulting, service and planning. Since entering China in 2013, it has been committed to extending its premium business segment to China's medical market and serving local medical institutions.
it is understood that the proposed health management company is to be registered in Beijing Haidian District, 81 Lucheng Road, Hospital 1 building, through the coordination of Beijing University Cancer Hospital has high-quality medical technology and medical experts resources, aimed at the establishment of high-end, systematic, professional cancer health management center. Health management company integrates the core functions of professional anti-cancer screening, VIP specialist clinic, oncology multidisciplinary consultation (MDT), telemedicine, "Second Opinion" service, tumor database establishment and application, gene screening and diagnostic technology application, clinical translational medicine, and other core functions, to achieve medical, teaching, learning, research, business integration, to provide full-life cycle management services for the middle and high-end population in the North and even the whole country.
, the relevant person in charge of Peking University Medicine said that the company in the existing tumor drug manufacturing, sales on the basis of the company is gradually accumulating more resources in the field of cancer. Relying on research and development resources will continue to strengthen the tumor drug species, the company also want to use the market, seeking further industrial chain extension in the field of cancer. In the early part of the company has jointly invested with Peking University Cancer Hospital to set up a cancer management company, and as a platform to invest in the establishment of health management companies. The company can effectively take advantage of the brand and resources of Peking University Cancer Hospital, to carry out cancer screening and diagnosis and treatment business, is conducive to the extension of the company's cancer treatment industry chain, enhance the company's overall market competitiveness and profitability.
also said that the company's development prospects for the medical services industry is optimistic, selectively cut into their own has a certain basis for anti-tumor medical services. The establishment of health management company, so that the company officially in-depth to the field of cancer diagnosis and treatment, can effectively draw on resources and experience, and gradually reserve the hospital's management capacity, conducive to the company's further development in the field of medical services.
also decided to increase the capital of Chongqing Southwest Synthetic Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Southwest Synthetic Pharmaceutical Co., Ltd., with land and real estate, to increase its registered capital from 2 million yuan to 250 million yuan, and to undertake the company's synthetic API business, in order to effectively integrate the api pharmaceutical business resources, reduce costs, and realize the professional development of API business and preparation business. In addition, the land of the Ma Liu project increased its capital from 2 million yuan to 55 million yuan, so as to improve the resource facilities and management efficiency of the Ma Liu manufacturing base project and realize the transformation of its control mode from the project to the company.
.